nirmatrelvir

Cadila Pharma receives licence from MPP for generic version of Pfizer’s Covid-19 oral antiviral – nirmatrelvir.

Cadila Pharma receives licence from MPP for generic version of Pfizer’s Covid-19 oral antiviral – nirmatrelvir. The drug is approved or under emergency use authorization for COVID-19 in many countries,

Read More